Showing 39,421 - 39,440 results of 40,910 for search '"college"', query time: 0.16s Refine Results
  1. 39421
  2. 39422
  3. 39423
  4. 39424
  5. 39425
  6. 39426
  7. 39427
  8. 39428
  9. 39429
  10. 39430
  11. 39431
  12. 39432

    Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma by Zhong L, Peng W, Sun J, Luo Y, Sheng H, Wu Y, Zhou T, Zhou C, Cao C

    Published 2025-01-01
    “…Liting Zhong,1,2,* Weiwei Peng,1,2,* Jingyuan Sun,3 Yongyi Luo,3 Hailong Sheng,4 Yi Wu,5 Tonggang Zhou,5 Chaoming Zhou,1,2 Chuanhui Cao1,3 1Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, People’s Republic of China; 2Department of Oncology, Ganzhou People’s Hospital, Ganzhou, Jiangxi, People’s Republic of China; 3Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; 4Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China; 5Department of Interventional Radiology, Ganzhou People’s Hospital, Ganzhou, Jiangxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chuanhui Cao, Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, No. 16 Meiguan Avenue, Ganzhou, Jiangxi, People’s Republic of China, Email huichuancao@163.comPurpose: The optimal timing for combining radiotherapy with immunotherapy in patients with hepatocellular carcinoma (HCC) remains uncertain and affects treatment efficacy and patient outcomes. …”
    Get full text
    Article
  13. 39433

    Echo- and B-Type Natriuretic Peptide-Guided Follow-Up versus Symptom-Guided Follow-Up: Comparison of the Outcome in Ambulatory Heart Failure Patients by Gani Bajraktari, Nicola Riccardo Pugliese, Andreina D’Agostino, Gian Marco Rosa, Pranvera Ibrahimi, Luan Perçuku, Mario Miccoli, Gian Giacomo Galeotti, Iacopo Fabiani, Roberto Pedrinelli, Michael Henein, Frank L. Dini

    Published 2018-01-01
    “…Recent European Society of Cardiology and American Heart Association/American College of Cardiology Guidelines did not recommend biomarker-guided therapy in the management of heart failure (HF) patients. …”
    Get full text
    Article
  14. 39434
  15. 39435
  16. 39436
  17. 39437
  18. 39438
  19. 39439
  20. 39440

    Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study by Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis

    Published 2024-10-01
    “…Efficacy assessments up to week 156 include American College of Rheumatology 20% response (ACR20), Disease Activity Score 28 using C-reactive protein of <2.6, Clinical Disease Activity Index of ≤2.8, Simplified Disease Activity Index of ≤3.3 and Boolean remission (1.0 and 2.0) with non-responder imputation.Results In patients with an inadequate response to methotrexate, 60.2% and 54.6% receiving de novo filgotinib 200 mg and 100 mg had an ACR20 at week 156, respectively, as did 67.3% and 59.5% of those who continued filgotinib 200 mg and 100 mg. …”
    Get full text
    Article